In Vitro |
Cycleanine inhibits L-type Ca-current (ICaL) of single rat ventricular cardiomyocytes in a voltage- and frequency-dependent manner[1]. Cycleanine shows modestly less potency against human OSE cells (normal) than the cancer cells[2]. Cycleanine (20 μM; 48 hours) exhibits cytotoxicity for Ovcar-8, A2780, Igrov-1, and Ovcar-4 cell lines with IC50s ranging from 7 to 14 μM[2]. Cycleanine (20 μM; 24 hours) results in significant PARP cleavage (a marker of apoptosis)[2]. Cycleanine (20 μM; 48 hours) causes a significant increase of the population of both early and late apoptotic cells[2]. Cell Cytotoxicity Assay[2] Cell Line: Ovcar-8 cells, A2780 cells, Igrov-1 cells, Ovcar-4 cells Concentration: 20 μM Incubation Time: 48 hours Result: Exhibited cytotoxicity for Ovcar-8, A2780, Igrov-1, and Ovcar-4 cell lines with IC50 values of 10 μM, 7.6 μM, 14 μM, 7.2 μM, respectively. Western Blot Analysis[2] Cell Line: Ovcar-8 cells Concentration: 20 μM Incubation Time: 24 hours Result: Induced 1.1-fold increase in PARP-1 cleavage compared with carboplatin. Apoptosis Analysis[2] Cell Line: Ovcar-8 cells Concentration: 20 μM Incubation Time: 48 hours Result: Caused a significant increase of the population of both early and late apoptotic cells. Cell Cycle Analysis[2] Cell Line: Ovcar-8 cells Concentration: 20 μM Incubation Time: 48 hours Result: Increased the percentage of Ovcar-8 cells in subG1.
|